Literature DB >> 606205

Substrate-typic changes of platelet monoamine oxidase activity in sub-types of schizophrenia.

L Demisch, H von der Mühlen, H J Bochnik, N Seiler.   

Abstract

Monoamine oxidase (MAO) activity has been measured in the platelets of controls (n = 42) and schizophrenic patients (n = 49) of three subtypes, using beta-phenylethylamine, p-tyramine, and tryptamine as substrates. Characteristic differences of MAO activity were observed between platelets of patients and controls; the differences were substrate-typic: decreased enzyme activity was found with all three substrates in platelets of the parnaoid subtype. With tryptamine, MAO activity was decreased in the platelets of all three sub-types of schizophrenia. With p-tyramine, MAO was low in patients with affective psychoses and paranoid schizophrenia. The value of MAO activity measurements as a means for distinguishing sub-types of schizophrenic disorders is improved by using two substrates; tryptamine and p-tyramine. Possible mechanisms of the substrate-typic changes of platelet MAO activity in schizophrenia are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606205     DOI: 10.1007/bf00341614

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  43 in total

1.  Letter: Platelet monoamine oxidase in schizophrenics.

Authors:  E G Shaskan; R E Becker
Journal:  Nature       Date:  1975-02-20       Impact factor: 49.962

2.  A routine assay procedure for monoamine oxidase and its application to human blood platelets.

Authors:  L Demisch; H J Bochnik; N Seiler
Journal:  Clin Chim Acta       Date:  1976-08-02       Impact factor: 3.786

3.  Effect of cortisone on monoamine oxidase of the liver of young & old rats.

Authors:  B S Gandhi; M S Kanungo
Journal:  Indian J Biochem Biophys       Date:  1974-06       Impact factor: 1.918

4.  Development of monoamine oxidase activity after chronic environmental stress in the rat.

Authors:  G Maura; A Vaccari; A Gemignani; F Cugurra
Journal:  Environ Physiol Biochem       Date:  1974

5.  Genetic control of platelet and plasma monoamine oxidase activity.

Authors:  A Nies; D S Robinson; K R Lamborn; R P Lampert
Journal:  Arch Gen Psychiatry       Date:  1973-06

6.  Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets.

Authors:  D S Robinson; J M Davis; A Nies; C L Ravaris; D Sylwester
Journal:  Arch Gen Psychiatry       Date:  1971-06

Review 7.  Neurotransmitter-related enzymes in the major psychiatric disorders: II. MAO and DBH in schizophrenia.

Authors:  R J Wyatt; D L Murphy
Journal:  Res Publ Assoc Res Nerv Ment Dis       Date:  1975

8.  Effects of monamine oxidase inhibitors on qualitive alterations ( Transformation ) of the catalytic properties of amine oxidases.

Authors:  V Z Gorkin; Z I Akopyan; I V Veryovkina; L N Stesina; M M Samed
Journal:  Biochem J       Date:  1971-02       Impact factor: 3.857

9.  Platelet monoamine oxidase activity in acute schizophrenia.

Authors:  W T Carpenter; D L Murphy; R J Wyatt
Journal:  Am J Psychiatry       Date:  1975-04       Impact factor: 18.112

10.  Menstrual cycle and ovarian hormone effects on plasma and platelet monoamine oxidase (MAO) and plasma dopamine-beta-hydroxylase (DBH) activities in the rhesus monkey.

Authors:  D E Redmond; D L Murphy; J Baulu; M G Ziegler; C R Lake
Journal:  Psychosom Med       Date:  1975 Sep-Oct       Impact factor: 4.312

View more
  3 in total

1.  Platelet monoamine oxidase activity in first-degree relatives of schizophrenic patients.

Authors:  P Propping; W Friedl
Journal:  Psychopharmacology (Berl)       Date:  1979-11       Impact factor: 4.530

2.  Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls.

Authors:  H Beckmann; G P Reynolds; M Sandler; P Waldmeier; J Lauber; P Riederer; W F Gattaz
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1983

Review 3.  Human platelet monoamine oxidase activity in health and disease: a review.

Authors:  M Sandler; M A Reveley; V Glover
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.